Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Express Scripts
Merck
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Cannabidivarin

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Cannabidivarin: Patents, clinical trial progress, indications

Cannabidivarin is an investigational drug.

There have been 6 clinical trials for Cannabidivarin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2016.

The most common disease conditions in clinical trials are Autism Spectrum Disorder, Disease, and Child Development Disorders, Pervasive. The leading clinical trial sponsors are GW Research Ltd, Montefiore Medical Center, and United States Department of Defense.

There are twenty-three US patents protecting this investigational drug and one hundred and twenty-one international patents.

Recent Clinical Trials for Cannabidivarin
TitleSponsorPhase
CBDV vs Placebo in Children With Prader Willi Syndrome PWSFoundation for Prader-Willi ResearchPhase 2
CBDV vs Placebo in Children With Prader Willi Syndrome PWSMontefiore Medical CenterPhase 2
Safety and Tolerability of Cannabidivarin (CBDV) in Children and Young Adults With Autism Spectrum DisorderGW Research LtdPhase 2

See all Cannabidivarin clinical trials

Clinical Trial Summary for Cannabidivarin

Top disease conditions for Cannabidivarin
Top clinical trial sponsors for Cannabidivarin

See all Cannabidivarin clinical trials

US Patents for Cannabidivarin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cannabidivarin   Start Trial Enhanced smokable therapeutic cannabis product and method for making same CMG PARTNERS, INC. (San Jose, CA)   Start Trial
Cannabidivarin   Start Trial Cannabis-based therapeutic product for treatment of chronic pain CMG PARTNERS, INC. (San Jose, CA)   Start Trial
Cannabidivarin   Start Trial Cannabinoid composition and products including .alpha.-tocopherol Constance Therapeutics, Inc. (San Francisco, CA)   Start Trial
Cannabidivarin   Start Trial Systems and methods for producing organic cannabis tincture   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cannabidivarin

Drugname Country Document Number Estimated Expiration Related US Patent
Cannabidivarin World Intellectual Property Organization (WIPO) 2018226899 2037-06-06   Start Trial
Cannabidivarin World Intellectual Property Organization (WIPO) 2018227017 2037-06-06   Start Trial
Cannabidivarin World Intellectual Property Organization (WIPO) 2018226899 2037-06-06   Start Trial
Cannabidivarin World Intellectual Property Organization (WIPO) 2018227017 2037-06-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Harvard Business School
McKinsey
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.